Post-Essential Thrombocythemia Myelofibrosis clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
PRT12396 in Participants With Select Myeloproliferative Neoplasms
open to eligible people ages 18 years and up
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Sacramento, California and other locations
Last updated: